Education
About Us
Working with TipRanks
Follow Us
USANA Health (USNA)
NYSE:USNA
Top Page
USANA Health
(NYSE:USNA)
63Neutral
USANA Health (USNA) vs. S&P 500 (SPY)
Market Cap
$519.40M
Dividend YieldN/A
Average Volume (3M)236.87K
Price to Earnings (P/E)15.1
Beta (1Y)0.86
Revenue Growth-2.69%
EPS Growth-43.24%
CountryUS
Employees1,700
SectorHealthcare
Sector Strength70
IndustryPackaged Foods
Share Statistics
EPS (TTM)1.82
Shares Outstanding18,860,016
10 Day Avg. Volume235,428
30 Day Avg. Volume236,873
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.62
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$50.50Price Target Upside83.37% Upside
Rating ConsensusHold
Number of Analyst Covering2
USANA Health Business Overview & Revenue Model
Company DescriptionUSANA Health Sciences, Inc. (USNA) is a global leader in the health and wellness industry, primarily focused on developing and manufacturing high-quality nutritional supplements, personal care, and weight management products. The company operates through a direct selling model, reaching a wide customer base in various markets worldwide. USANA's core offerings include vitamins and dietary supplements designed to support overall health and well-being, as well as skincare products aimed at enhancing personal care routines.
How the Company Makes MoneyUSANA Health Sciences generates revenue primarily through the sale of its nutritional and personal care products, which are distributed via a direct selling model. Independent distributors, also known as 'associates,' play a key role in marketing and selling USANA's products to consumers, earning commissions on their sales. This multi-level marketing strategy allows USANA to expand its reach and maintain a flexible and motivated sales force. Additionally, the company benefits from a robust customer loyalty program, which encourages repeat purchases and enhances customer retention. Significant partnerships with research institutions also contribute to product development and innovation, ensuring USANA remains competitive in the health and wellness sector.
USANA Health Financial Statement Overview
Summary
USANA Health demonstrates strong gross profit margins and a solid balance sheet characterized by low leverage and strong equity. However, the company faces challenges with declining revenues, reduced net profit margins, and lower free cash flow growth. The overall financial position remains stable, but the company needs to address revenue and net income declines for improved financial performance.Income Statement
USANA Health has experienced a declining revenue trend over the last few years, with a revenue decrease of approximately 7% from 2023 to 2024. The gross profit margin in 2024 was strong at around 81%, indicating efficient cost management. However, net profit margin decreased to about 4.92% in 2024 compared to 6.92% in 2023, reflecting pressure on net income. Despite this, the company maintains a solid EBIT margin at 7.76% in 2024. Overall, the company shows strong gross margins but faces challenges with declining revenues and net profitability.65
Positive
Balance Sheet
USANA Health's balance sheet reflects a strong equity position with an equity ratio of approximately 71.1% in 2024, indicating financial stability and low leverage. The debt-to-equity ratio remains low at 0.04, demonstrating conservative financial management and limited reliance on debt. Return on equity decreased to 7.9% in 2024 from 12.8% in 2023, indicating reduced profitability on equity investments. Overall, the company's balance sheet is robust, supported by strong equity and low debt levels, although ROE has seen a decline.70
Positive
Cash Flow
The cash flow analysis shows a modest decrease in free cash flow from 2023 to 2024 by about 9.3%. The operating cash flow to net income ratio is healthy, suggesting efficient cash generation relative to net income. However, the free cash flow to net income ratio has declined, reflecting less cash available after capital expenditures. Despite these challenges, USANA Health continues to generate positive operating cash flow. Overall, cash flows are positive, but there is a downward trend in free cash flow growth.60
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 854.50M | 921.01M | 998.60M | 1.19B | 1.13B | Gross Profit |
| 693.29M | 744.32M | 804.71M | 968.57M | 925.53M | EBIT |
| 66.32M | 93.07M | 107.61M | 170.19M | 176.49M | EBITDA |
| 98.86M | 123.11M | 130.22M | 192.89M | 200.96M | Net Income Common Stockholders |
| 42.03M | 63.79M | 69.35M | 116.50M | 124.66M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 181.77M | 330.42M | 288.42M | 239.83M | 311.92M | Total Assets |
| 748.19M | 632.76M | 596.55M | 577.74M | 640.89M | Total Debt |
| 23.00M | 13.21M | 6.89M | 7.08M | 8.62M | Net Debt |
| -158.77M | -317.21M | -281.53M | -232.75M | -303.30M | Total Liabilities |
| 161.86M | 135.56M | 162.08M | 182.62M | 199.24M | Stockholders Equity |
| 532.11M | 497.20M | 434.47M | 395.12M | 441.65M |
| Cash Flow | Free Cash Flow | |||
| 50.92M | 56.15M | 93.50M | 108.46M | 145.31M | Operating Cash Flow |
| 60.99M | 70.64M | 103.90M | 121.23M | 160.40M | Investing Cash Flow |
| -213.09M | -11.97M | -12.37M | -14.19M | -33.96M | Financing Cash Flow |
| 9.55M | -14.24M | -30.09M | -181.41M | -59.44M |
USANA Health Technical Analysis
Neutral
27.54
Price Trends
28.28
Negative
31.60
Negative
35.55
Negative
Market Momentum
-0.73
Negative
55.97
Neutral
66.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For USNA, the sentiment is Neutral. The current price of 27.54 is above the 20-day moving average (MA) of 25.36, below the 50-day MA of 28.28, and below the 200-day MA of 35.55, indicating a neutral trend. The MACD of -0.73 indicates Negative momentum. The RSI at 55.97 is Neutral, neither overbought nor oversold. The STOCH value of 66.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for USNA.
USANA Health Risk Analysis
USANA Health disclosed 41 risk factors in its most recent earnings report. USANA Health reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
USANA Health Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $152.37M | 21.48 | 25.67% | 1.30% | 0.57% | 155.00% | |
64 Neutral | $218.47M | 29.26 | 4.98% | ― | 2.03% | -47.76% | |
63 Neutral | $519.40M | 15.10 | 6.78% | ― | -2.69% | -43.24% | |
58 Neutral | $506.49M | ― | -6.77% | ― | -5.50% | 89.98% | |
51 Neutral | $5.35B | 3.41 | -40.48% | 2.89% | 17.92% | 2.25% | |
47 Neutral | $698.26M | 2.76 | -31.74% | ― | -1.37% | 75.47% | |
45 Neutral | $266.23M | ― | -19.41% | ― | -6.68% | -9.71% |
* Healthcare Sector Average
Performance Comparison
USNA
USANA Health
27.54
-13.98
-33.67%
HLF
Herbalife
7.07
-1.58
-18.27%
NATR
Nature's Sunshine Products
11.97
-7.48
-38.46%
STKL
SunOpta
4.32
-2.23
-34.05%
HAIN
Hain Celestial
2.97
-3.17
-51.63%
LFVN
LifeVantage
12.35
6.34
105.49%
USANA Health Earnings Call Summary
Earnings Call Date:Apr 22, 2025
(Q1-2025)
| % Change Since: 13.61%|
Next Earnings Date:Jul 29, 2025
Earnings Call Sentiment Positive
USANA's earnings call presented a strong start to fiscal year 2025 with significant growth in key markets and successful product launches. The acquisition of Hiya is performing well, contributing positively to sales. However, cautious consumer sentiment and uncertainty around trade policies pose potential challenges. Nonetheless, the proactive strategies in place provide confidence in navigating these uncertainties.Q1-2025 Updates
Positive Updates
Strong Overall Start to Fiscal Year 2025
USANA reported a 12% year-over-year growth in consolidated net sales in constant currency, aligning with internal expectations. This includes the first full quarter contribution from Hiya.
Growth in Key Markets
Mainland China experienced a 6% growth in net sales and a 4% increase in active customers sequentially. South Korea also showed sequential growth in net sales and active customers.
Successful Product Launches
USANA expanded its product offerings in several markets, including new products in China, leading to higher-than-expected sales performances.
Hiya Acquisition Performance
Hiya showed strong growth in net sales and active monthly subscribers, with successful product launches such as Kids Daily Greens exceeding expectations.
Proactive Trade Strategy
USANA has built up inventory to mitigate potential tariff impacts and has explored alternative sourcing relationships to address emerging trade policies.
Negative Updates
Cautious Consumer Sentiment
Overall consumer sentiment remains cautious in key markets, posing potential challenges to sustaining growth.
Uncertainty in Trade Policies
The impact of potential trade policies and tariffs remains uncertain, which could affect future financial results.
Slow Progress in India
Despite high expectations, growth in the Indian market has been slow and requires continued focus to gain momentum.
Company Guidance
During the call, USANA Health Sciences provided guidance for the fiscal year 2025, highlighting a positive start with consolidated net sales growing by 12% year-over-year in constant currency. The company observed sequential growth in net sales and active customers for the second consecutive quarter, with a notable 6% and 4% increase in their largest market, Mainland China. The newly acquired Hiya business also showed strong performance, with significant growth in net sales and active monthly subscribers. While USANA remains on track to meet its sales guidance, the potential impact of tariffs and trade policies remains uncertain. The company has proactively built inventory to mitigate tariff exposure and is exploring alternative sourcing relationships. Overall, USANA is optimistic about its growth trajectory, driven by product innovation and strategic initiatives.USANA Health Corporate Events
Business Operations and StrategyFinancial Disclosures
USANA Health Reports Q1 2025 Financial Results
Neutral
Apr 22, 2025
USANA Health Sciences reported its financial results for the first quarter of 2025, showing a 10% increase in net sales compared to the same period in 2024, despite a decline in net earnings and diluted EPS. The company reiterated its full-year outlook, highlighting strong growth in its Hiya direct-to-consumer business and a modest increase in direct sales and active customers. USANA is confident in its growth trajectory, despite global economic uncertainties, and continues to manage its supply chain effectively to mitigate potential impacts from trade policies and tariffs.
Spark’s Take on USNA Stock
According to Spark, TipRanks’ AI Analyst, USNA is a Neutral.
USANA Health’s overall stock score reflects strong financial stability with a solid balance sheet and low leverage. However, declining revenues and net profit margins, coupled with downward technical indicators, pose challenges. The strategic acquisition and positive guidance from the earnings call moderately offset these concerns, contributing to an overall stable outlook.
To see Spark’s full report on USNA stock, click here.
M&A TransactionsBusiness Operations and StrategyFinancial Disclosures
USANA Health Acquires Hiya Health to Boost Growth
Neutral
Feb 25, 2025
USANA Health Sciences reported a decline in financial performance for the fiscal year 2024, with net sales dropping to $855 million from $921 million in 2023, and net earnings falling to $42 million from $63.8 million. The company’s acquisition of Hiya Health Products, completed in December 2024, is expected to bolster its market position in the children’s health segment, although Hiya’s contribution to the year’s financial results was minimal. Despite challenges in the Asia Pacific market, USANA saw growth in the Americas and Europe, and the company remains optimistic about its growth strategy for 2025, projecting net sales between $920 million and $1 billion.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.